ArticleFrontiers in cardiovascular medicine2022
Hydrogen Gas Inhalation Regressed Coronary Artery Aneurysm in Kawasaki Disease-Case Report and Article Review.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- HMolecular and cellular biochemistry · 2026Review
- Hydrogen Gas Inhalation Treatment for Coronary Artery Lesions in a Kawasaki Disease Mouse Model.Life (Basel, Switzerland) · 2024Article
- Diagnosis, Progress, and Treatment Update of Kawasaki Disease.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old and is among the most common acquired heart disease in developed countries, particularly in Asia. No effective treatment is currently available for aneurysm formation in KD. In this report, we showed a KD patient with an aneurysm over the right coronary artery with a size of 6.08 mm in diameter and 35 mm in length, which completely regressed to within normal range after hydrogen inhalation within 4 months after disease onset. This 10-year-old KD patient was diagnosed on the 12th day of disease onset with incomplete presentation of KD symptoms. Intravenous immunoglobulin was prescribed after KD diagnosis was confirmed by the formation of a coronary artery aneurysm. Once discharged from the hospital, the family used hydrogen inhalation (77% hydrogen and 23% oxygen) at home with nasal cannula 1 h per day. The aneurysm was found to be completely regressed at the 4-month follow-up (day 138 of the illness). The follow-up laboratory data showed complete blood cell count, differential count, electrolytes, liver enzyme, and renal function to all be within normal range. This is the first study to report an aneurysm from KD with regression under supplementary therapy with hydrogen gas inhalation and no other complications. Therefore, hydrogen gas inhalation may be an alternative anti-free radical or anti-oxidant therapy for KD, but further study is still required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.